Harriet E Gee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1147948/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2022, 113, 40-59.	0.4	14
2	Impact of <scp>DNA</scp> damage response defects in cancer cells on response to immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 546-559.	0.9	5
3	Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas. International Journal of Molecular Sciences, 2021, 22, 7265.	1.8	26
4	Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. BMC Cancer, 2021, 21, 940.	1.1	5
5	Radiation therapy in the prevention and management of brain metastases in patients with small cell lung cancer: a narrative review. Chinese Clinical Oncology, 2021, .	0.4	1
6	Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports, 2020, 10, 10226.	1.6	10
7	DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). Neuro-Oncology, 2020, 22, iii289-iii289.	0.6	0
8	DIPG-17. IMPROVING THE RADIOSENSITIVITY OF DIFFUSE INTRINSIC PONTINE GLIOMAS BY MODULATING BIOENERGETIC PATHWAYS. Neuro-Oncology, 2019, 21, ii72-ii72.	0.6	0
9	Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. Disease Markers, 2019, 2019, 1-12.	0.6	9
10	Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 102-115.	0.9	28
11	High-Risk Cutaneous Squamous Cell Carcinoma. Current Otorhinolaryngology Reports, 2018, 6, 120-128.	0.2	2
12	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. Cancer Research, 2018, 78, 501-515.	0.4	105
13	Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers Journal of Clinical Oncology, 2018, 36, e18046-e18046.	0.8	0
14	<i>In vivo</i> dosimetric impact of breast tissue expanders on postâ€mastectomy radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 138-145.	0.9	27
15	Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 2016, 16, 86.	1.1	51
16	Programmed death ligand 1 expression in tripleâ€negative breast cancer is associated with tumourâ€infiltrating lymphocytes and improved outcome. Histopathology, 2016, 69, 25-34.	1.6	177
17	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1104-1114.	0.4	18
18	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	2.5	102

HARRIET E GEE

#	Article	IF	CITATIONS
19	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91, 749-758.	1.7	64
20	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. Cancer Research, 2011, 71, 5635-5645.	0.4	285
21	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer, 2011, 104, 1168-1177.	2.9	244
22	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	2.0	215
23	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	1.1	276
24	MicroRNA-10b and breast cancer metastasis. Nature, 2008, 455, E8-E9.	13.7	134